Clinical distribution and antimicrobial resistance of 47 strains of Ralstonia mannitolilytica
10.16718/j.1009-7708.2025.04.009
- VernacularTitle:解甘露醇罗尔斯顿菌47株的临床分布特征及耐药性分析
- Author:
Qiongya HU
1
;
Jiao PENG
;
Chuangjie YANG
;
Jingyong SUN
;
Shuzhen XIAO
Author Information
1. 三门峡市中医院检验科,河南三门峡 472000
- Publication Type:Journal Article
- Keywords:
Ralstonia mannitolilytica;
antimicrobial agent;
antimicrobial resistance rate
- From:
Chinese Journal of Infection and Chemotherapy
2025;25(4):413-417
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical distribution and antimicrobial susceptibility of Ralstonia mannitolilytica strains isolated from clinical specimens at a tertiary hospital in Shanghai.The results could inform better clinical treatment of R.mannitolilytica.Methods A total of 47 R.mannitolilytica isolated from January 2022 to August 2024 were collected.The clinical data of patients from whom these strains were isolated were reviewed and analyzed.Results The 47 strains of R.mannitolilytica were mainly isolated from hematology department(85.1％,40/47)and intensive care unit(4.3％,2/47).In the 47 patients with R.mannitolilytica isolate,83.0％had hematological disease and 85.1％stayed in hospital for at least 28 days.Overall,63.8％of the 47 patients used antibiotics for at least 3 weeks and 76.6％of the patients used at least three types of antibiotics during hospital stay.All of the 47 R.mannitolilytica strains were resistant to aztreonam,while 84.6％,83.3％,70.4％,and 69.6％of the strains were resistant to meropenem,ticarcillin-clavulanate acid,ceftazidime,and piperacillin-tazobactam,respectively,58.7％,55.8％,52.2％,and 42.2％of the strains were resistant to amikacin,tobramycin,cefepime,and imipenem,respectively.In contrast,88.1％,83.3％,82.9％,67.4％and 60.5％of the strains were susceptible to minocycline,doxycycline,cotrimoxazole,ciprofloxacin,and levofloxacin,respectively.Conclusions Most of the R.mannitolilytica strains were multi-drug resistant.The bacteria is more prevalent in patients with hematological disorders and long-term treatment with multiple broad-spectrum antimicrobial agents.
